📣 VC round data is live. Check it out!

Exact Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Exact Sciences and similar public comparables like Labcorp, Quest Diagnostics, Illumina, Hologic and more.

Exact Sciences Overview

About Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.


Founded

1995

HQ

United States

Employees

7.2K

Financials (FY)

Revenue:
Net Income:

EV

$21B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Exact Sciences Stock Performance

Exact Sciences has current market cap of $20B, and enterprise value of $21B.

Market Cap Evolution


Exact Sciences' stock price is $103.50.

Exact Sciences share price increased by 83.9% in the last year.

See more trading valuation data for Exact Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$21B$20B0.0%83.9%

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Exact Sciences Valuation Multiples

Exact Sciences Financial Valuation Multiples

As of May 13, 2026, Exact Sciences has market cap of $20B and EV of $21B.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Exact Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

Exact Sciences Competitors

Exact Sciences competitors include Labcorp, Quest Diagnostics, Illumina, Hologic, United Imaging, Guardant Health, GE HealthCare, Revvity, Natera and bioMérieux.

Most Exact Sciences public comparables operate across Medical Imaging & Diagnostics, Diagnostics & Genomics, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Labcorp1.9x1.9x11.4x11.1x
Quest Diagnostics2.4x2.4x12.4x12.1x
Illumina5.3x5.2x15.8x18.4x
Hologic
United Imaging6.4x6.0x34.9x35.3x
Guardant Health13.7x12.2x(60.5x)(65.4x)
GE HealthCare1.8x1.7x9.6x9.8x
Revvity4.7x4.8x16.0x15.7x

This data is available for Pro users. Sign up to see all Exact Sciences competitors and their valuation data.

Start Free Trial

Exact Sciences M&A Activity

Exact Sciences has acquired 13 companies to date.

Last acquisition by Exact Sciences was on September 12th 2023. Exact Sciences acquired Resolution Bioscience for $54M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Exact Sciences

Resolution Bioscience
OmicEra Diagnostics
PreventionGenetics
PFS Genomics
Description
Resolution Bioscience is a precision oncology company offering liquid biopsy tests analyzing cell-free DNA for cancer mutations and minimal residual disease. Its Resolution ctDx assay detects over 500 biomarkers from blood samples, supporting therapies like EGFR inhibitors. Kirkland, Washington-headquartered, it develops companion diagnostics for pharma trials. Founded in 2015, the firm collaborates with MSKCC and supplies panels to 100+ labs worldwide.
OmicEra Diagnostics is a Bengaluru-based proteomics startup leveraging mass spectrometry and AI for medical diagnostics. The company develops biomarker panels for diseases like cancer and metabolic disorders, using high-throughput plasma proteomics to profile thousands of proteins per sample. Committed to open-source software, it offers reproducible assays and data analysis pipelines. Founded in 2019, OmicEra collaborates with hospitals in India for clinical validation and commercialization of precision health tests.
PreventionGenetics is a Marshfield, Wisconsin-based clinical laboratory offering genetic testing for over 4,000 genes. Launched PGxome whole exome sequencing in 2014, it detects rare disorders via next-generation sequencing. The lab processes deletion/duplication analyses and serves U.S. physicians with rapid turnaround reports. PreventionGenetics holds CLIA certification for diagnostic accuracy.
PFS Genomics is a US precision medicine company developing genomic tests for breast cancer risk stratification. Based in Nashville since 2018, its assays guide treatment decisions using polygenic scores.
HQ CountryUnited StatesGermanyUnited StatesUnited States
HQ City
Seattle, WA
Munich
Boston, MA
Nashville, TN
Deal Date12 Sep 20234 May 202210 Jan 20224 May 2021
Valuation$54M$19M$190M$34M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Exact Sciences acquisitions and their M&A valuation multiples.

Start Free Trial

Exact Sciences Investment Activity

Exact Sciences has invested in 3 companies to date.

Latest investment by Exact Sciences was on March 2nd 2026. Exact Sciences invested in KeyCare in their $27M Series A round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Exact Sciences

KeyCare
Freenome
Freenome
Thrive Earlier Detection
Description
KeyCare delivers a virtual care platform integrated with Epic's electronic health records system. Nashville-based, it equips health systems like Vanderbilt University Medical Center with telemedicine tools for scheduling, video visits, and asynchronous messaging. Launched in 2020, KeyCare expands access through patient portals that support chronic disease management and urgent care, processing millions of virtual encounters annually. The platform complies with HIPAA and connects with over 20 Epic-using hospitals across the U.S. Southeast.
Freenome is a South San Francisco-headquartered private biotechnology company specializing in early cancer detection via blood tests. It pioneers non-invasive screening using machine learning to analyze multiomics data for proactive management of cancers and other diseases. The approach aims to make advanced diagnostics accessible through innovative blood-based solutions.
Freenome is a South San Francisco-headquartered private biotechnology company specializing in early cancer detection via blood tests. It pioneers non-invasive screening using machine learning to analyze multiomics data for proactive management of cancers and other diseases. The approach aims to make advanced diagnostics accessible through innovative blood-based solutions.
Thrive Earlier Detection is a cancer diagnostics company developing CancerSEEK, a multi-cancer liquid biopsy test detecting early-stage tumors through blood analysis. Baltimore-based since 2015 and backed by Third Rock Ventures, Section 32, and Exact Sciences, it integrates results into routine medical care.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Chicago, IL
San Francisco, CA
San Francisco, CA
Deal Date2 Mar 20266 Aug 20256 Aug 202530 May 2019
RoundSeries AUndisclosed stageStrategic investmentSeries A
Raised$27M$50M$50M$110M
Investors8VC; Allina Health; Bold Capital Partners; Edge; Exact Sciences; HealthX Ventures; Ikigai Growth Partners; LRVHealth; UCM Ventures; WellSpan HealthExact SciencesExact SciencesBiomatics Capital Partners; Camden Partners; Casdin Capital; Cowin Venture; Exact Sciences; Gamma3; Invus; S32; The Blue Venture Fund; Third Rock Ventures
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Exact Sciences investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Exact Sciences

When was Exact Sciences founded?Exact Sciences was founded in 1995.
Where is Exact Sciences headquartered?Exact Sciences is headquartered in United States.
How many employees does Exact Sciences have?As of today, Exact Sciences has over 7K employees.
Who is the CEO of Exact Sciences?Exact Sciences' CEO is Kevin T. Conroy.
Is Exact Sciences publicly listed?Yes, Exact Sciences is a public company listed on Moscow Exchange.
What is the stock symbol of Exact Sciences?Exact Sciences trades under EXAS-RM ticker.
When did Exact Sciences go public?Exact Sciences went public in 2001.
Who are competitors of Exact Sciences?Exact Sciences main competitors include Labcorp, Quest Diagnostics, Illumina, Hologic, United Imaging, Guardant Health, GE HealthCare, Revvity, Natera, bioMérieux.
What is the current market cap of Exact Sciences?Exact Sciences' current market cap is $20B.
Is Exact Sciences profitable?No, Exact Sciences is not profitable.
How many companies Exact Sciences has acquired to date?As of May 2026, Exact Sciences has acquired 13 companies.
What was the largest acquisition by Exact Sciences?$3B acquisition of Genomic Health on 29th July 2019 was the largest M&A Exact Sciences has done to date.
What companies Exact Sciences acquired?Exact Sciences acquired Genomic Health, Thrive Earlier Detection, Base Genomics, PreventionGenetics, Ashion Analytics, Resolution Bioscience, Viomics, Paradigm Diagnostics, Biomatrica, PFS Genomics, and 3 other companies.
In how many companies Exact Sciences has invested to date?As of May 2026, Exact Sciences has invested in 3 companies.
What was the last Exact Sciences investment?On 2nd March 2026 Exact Sciences invested in KeyCare, participating in a $27M Series A round, alongside 8VC, Allina Health, Bold Capital Partners, Edge, HealthX Ventures, Ikigai Growth Partners, LRVHealth, UCM Ventures, and WellSpan Health.
In what companies Exact Sciences invested in?Exact Sciences invested in Thrive Earlier Detection, Freenome, and KeyCare.

See public comps similar to Exact Sciences

Lists including Exact Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial